QIAGEN’s planned $225M cash acquisition of Parse Biosciences, announced in November 2025, marked a major milestone for a company built directly on research from the University of Washington. Parse was founded in 2018 by Alex Rosenberg and Charles Roco, both PhD trainees in Georg Seelig’s lab, which was part of the UW Center for Synthetic Biology at the time. Seelig joined them as a co‑founder as they translated their split‑pool barcoding method—first described in their 2018 Science paper on combinatorial indexing for single‑cell RNA‑seq (Science. 2018 Mar 15;360(6385):176–182. doi: 10.1126/science.aam8999) —into an accessible, instrument‑free single‑cell sequencing platform. Parse licensed a substantial UW intellectual‑property portfolio to commercialize the technology, including more than 30 issued patents covering core aspects of split‑pool barcoding and scalable single‑cell profiling. After launching its first products in 2021, the company grew to over 110 employees and 3,000 customers in more than 40 countries. The acquisition underscored how UW‑originated synthetic biology continues to seed globally impactful technologies and strengthen the region’s leadership in scalable single‑cell analysis.